Pembrolizumab (+) Berahyaluronidase alfa

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Classical Hodgkin Lymphoma Recurrent

Conditions

Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory

Trial Timeline

Oct 14, 2024 → Nov 8, 2028

NCT ID

NCT06504394

About Pembrolizumab (+) Berahyaluronidase alfa

Pembrolizumab (+) Berahyaluronidase alfa is a phase 2 stage product being developed by Merck for Classical Hodgkin Lymphoma Recurrent. The current trial status is active. This product is registered under clinical trial identifier NCT06504394. Target conditions include Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent.

What happened to similar drugs?

0 of 2 similar drugs in Classical Hodgkin Lymphoma Recurrent were approved

Approved (0) Terminated (1) Active (1)

🔄Camrelizumab + Investigator's choice of ChemotherapyJiangsu Hengrui MedicinePhase 3

❌Tislelizumab + Salvage ChemotherapyBeOne MedicinesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06504394	Phase 2	Active	Oct 14, 2024	Nov 8, 2028	Classical Hodgkin Lymphoma Recurrent
NCT06041802	Phase 2	Active	Oct 20, 2023	Mar 31, 2028	Squamous Cell Carcinoma

Competing Products

11 competing products in Classical Hodgkin Lymphoma Recurrent

See all competitors

Product	Company	Stage	Hype Score
Camrelizumab + Investigator's choice of Chemotherapy	Jiangsu Hengrui Medicine	Phase 3	36
Sabestomig (AZD7789)	AstraZeneca	Phase 1	29
Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin	Merck	Phase 2	42
Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone	Merck	Phase 2	35
Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate	Merck	Phase 2	31
Carboplatin + Etoposide + Ifosfamide + Pembrolizumab	Merck	Phase 2	31
Panobinostat	Novartis	Phase 2	35
PD1	Innovent Biologics	Phase 2	35
Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine	Bristol Myers Squibb	Phase 1	33
Tislelizumab + Salvage Chemotherapy	BeOne Medicines	Phase 3	29
GEN3017	Genmab	Phase 1/2	21